• Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany
  • Evaluation of gaxilose (LacTEST 0.45 g) as a marker of intestinal barrier integrity in patients with celiac disease

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Study of Topical Chloramphenicol vs Topical Ciprofloxacin for Treating Otorrhea in Adults with Chronic Suppurative Otitis Media

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Spain
  • Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    France Spain
  • Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Belgium Germany Hungary Italy Poland
  • Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Efficacy of colistimethate sodium and ciprofloxacin for eradicating primary Pseudomonas aeruginosa infection in adults with bronchiectasis

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Spain
  • Safety and Efficacy of Dasatinib in Reducing HIV-1 Reservoir, Inflammation, and Immune Senescence in People with HIV on Long‑Term Antiretroviral Therapy

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Belgium Denmark France Italy Spain

powered by